ecopipam

Ecopipam (UNII-0X748O646K) is a potent, selective, and orally active antagonist of dopamine D1/D5 receptors, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam demonstrates more than 40-fold selectivity over D2, D4, 5-HT, and α2a receptors (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). It is used in research on schizophrenia and obesity.

Ecopipam (SCH 39166) hydrobromide is a highly potent, specific, and orally active dopamine D1/D5 receptor antagonist with K i values of 1.2 nM for D1 and 2.0 nM for D5 receptors. It shows over 40-fold greater selectivity for D1/D5 over D2, D4, 5-HT, and α2a receptors, with K i values of 0.98, 5.52, 0.08, and 0.73 μM, respectively, and is relevant for schizophrenia and obesity research.

Ecopipam (SCH 39166) hydrochloride is a highly potent, selective, and orally active antagonist of dopamine D1/D5 receptors. It exhibits impressive binding affinities, with Ki values of 1.2 nM and 2.0 nM for D1 and D5 receptors, respectively. Ecopipam hydrochloride demonstrates remarkable selectivity, displaying over 40-fold selectivity compared to D2, D4, 5-HT, and α2a receptors, with Ki values of 0.98 μM, 5.52 μM, 0.08 μM, and 0.73 μM, respectively. Its application extends to various areas of research, including schizophrenia, cocaine addiction, and obesity [1] [3].